J
Joel M. Reid
Researcher at Mayo Clinic
Publications - 274
Citations - 11448
Joel M. Reid is an academic researcher from Mayo Clinic. The author has contributed to research in topics: Pharmacokinetics & Medicine. The author has an hindex of 50, co-authored 248 publications receiving 10094 citations. Previous affiliations of Joel M. Reid include Oregon Health & Science University & Upjohn.
Papers
More filters
Journal ArticleDOI
Pharmacokinetics of Intravitreal Bevacizumab (Avastin)
TL;DR: The vitreous half-life of 1.25 mg intravitreal bevacizumab (Avastin) is 4.32 days in a rabbit eye, compared with 4.88 days and 6.86 days for the aqueous and serum values, respectively.
Journal ArticleDOI
CD38 Dictates Age-Related NAD Decline and Mitochondrial Dysfunction through an SIRT3-Dependent Mechanism
Juliana Camacho-Pereira,Juliana Camacho-Pereira,Mariana G. Tarragó,Claudia C.S. Chini,Veronica Nin,Carlos Escande,Gina M. Warner,Amrutesh S. Puranik,Renee A. Schoon,Joel M. Reid,Antonio Galina,Eduardo N. Chini +11 more
TL;DR: It is demonstrated that expression and activity of the NADase CD38 increase with aging and that CD38 is required for the age-related NAD decline and mitochondrial dysfunction via a pathway mediated at least in part by regulation of SIRT3 activity.
Journal ArticleDOI
Pharmacokinetics of intravitreal ranibizumab (Lucentis).
TL;DR: Although vitreous concentrations of ranibizumab declined in a monoexponential fashion with a half-life of 2.88 days, concentrations of >0.1 microg/ml ranibzumab were maintained in the Vitreous humor for 29 days, whereas small amounts of intravitreal bevacizumAB have been detected in the serum and fellow uninjected eye.
Journal ArticleDOI
Phase I and Pharmacodynamic Study of the Oral MEK Inhibitor CI-1040 in Patients With Advanced Malignancies
Patricia M. LoRusso,Alex A. Adjei,Mary Varterasian,Shirish Gadgeel,Joel M. Reid,David Y. Mitchell,Lorelei J. Hanson,Pamela DeLuca,Laura M. Bruzek,Jill Piens,Peggy Asbury,Keri Van Becelaere,Roman Herrera,Judith Sebolt-Leopold,Mark B. Meyer +14 more
TL;DR: Both target suppression and antitumor activity were demonstrated in this phase I study of CI-1040, a small-molecule inhibitor of the dual-specificity kinases MEK -1 and MEK2 in patients with advanced malignancy.
Journal ArticleDOI
Modulating Pharmacokinetics, Tumor Uptake and Biodistribution by Engineered Nanoparticles
Rochelle R. Arvizo,Oscar R. Miranda,Daniel F. Moyano,Chad A. Walden,Karuna Giri,Resham Bhattacharya,J. David Robertson,Vincent M. Rotello,Joel M. Reid,Priyabrata Mukherjee +9 more
TL;DR: In this article, a family of structurally homologous nanoparticles, including neutral (TEGOH), zwitterionic (Tzwit), negative (TCOOH), and positive (TTMA), were injected into mice to investigate how surface properties such as charge played an important role in their in vivo behavior.